Only the Kidney Disease: Improving Global Outcomes (KDIGO) anemia guideline published in 2012 defined ESA hyporesponsiveness as “patients who have no increased Hb concentration from baseline after the first month of ESA treatment on appropriate weight-based dose [28]. This evidence concerns the gene GSTM1 and anemia (phenotype).